MISTIE-II 365-Day Results Presented at 2013 International Stroke Conference


Dr. Daniel Hanley, co-principal investigator for the MISTIE clinical trial, was a featured speaker this week at the 2013 International Stroke conference (ISC) in Honolulu as he presented 365-day results from this phase-II clinical trial. MISTIE is an acronym for Minimally Invasive Surgery + rt-PA for Intracerebral Hemorrhage (ICH) Evacuation. ICH is a type of stroke caused by bleeding within the brain, often the result of uncontrolled hypertension. It is also referred to as cerebral stroke or hemorrhagic stroke.

This recently-completed proof-of-concept trial evaluated the use of tPA (a thrombolytic or clot-busting drug) delivered via a catheter placed under CT (a series of x-ray images) guidance. Data from the 123 patients enrolled across 26 medical centers provides ground-breaking evidence, which now needs to be verified in a larger phase-III trial, that this technique offers future promise for reducing the high rate of death and serious disability in ICH patients. Preliminary results were presented at last year's conference. Now that study participants have reached the one-year mark, the final results are even more encouraging. A summary of these results have been published on the American Stroke Society's ISC website -- scroll to the bottom to see Dr. Hanley's late-breaking presentation materials.

Continue reading

MISTIE-3 Site Locations